Increasing prevalence of nose bleeding to accelerate the growth of the epistaxis market

 

Epistaxis, also known as Perleche, occurs when a small amount of blood in the nasal cavities (the mucous membrane that protects the sensitive membranes of the nose) forms a crust on the back of the tongue, which blocks the tip of the nose and causes a nosebleed. Epistaxis can cause bleeding or nosebleeds, especially if there is not enough blood flow through the blocked area, which inflates and deflates to provide immediate nosebleed relief. The most affected areas are the soft palate (the area behind the front teeth), the ethmoid region of the nose, and the conjunctiva.

North America is expected to dominate the global epistaxis market in the near future and this is accredited to the high prevalence of hypertension in the region. According to the U.S. Department of Health & Human Services, Nearly half of adults in the United States (108 million, or 45%) have hypertension defined as a systolic blood pressure ≥ 130 mm Hg or a diastolic blood pressure ≥ of 80 mm Hg or are taking medication for hypertension. Hypertension is one of the major causes of nose bleeding.

The increasing prevalence of nose bleeding due to dry climate and lack of humidity in the atmosphere is significantly propelling the growth of the epistaxis market. According to the National Center for Biotechnology Information, about 60% of people have experienced a nosebleed during their life, and only 10% of nosebleeds are severe enough to warrant treatment/medical intervention. They occur most commonly in children ranging from 2 to 10 years old and the elderly ranging from 50 to 80 years old. Moreover, the growing incidence of the heart-related disorder is leading to hypertension which is also one of the causes of nose bleeding, thereby propelling the growth of the epistaxis market. According to the World Health Organization, an estimated 1.13 billion people worldwide have hypertension, most (two-thirds) living in low- and middle-income countries.

Key Developments:

1. In September 2017, Optinose, an ENT / Allergy specialty pharmaceutical company, announced that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application (NDA) for XHANCE (previously referred to by the development name OPN-375) for the treatment of nasal polyps in patients 18 years of age and older

2. In June 2019, The U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis